If you're interested in broad exposure to the Healthcare - Broad segment of the equity market, look no further than the Invesco S&P SmallCap Health Care ETF (PSCH), a passively managed exchange traded fund launched on 04/07/2010.
Passively managed ETFs are becoming increasingly popular with institutional as well as retail investors due to their low cost, transparency, flexibility and tax efficiency. They are excellent vehicles for long term investors.
Investor-friendly, sector ETFs provide many options to gain low risk and diversified exposure to a broad group of companies in particular sectors. Healthcare - Broad is one of the 16 broad Zacks sectors within the Zacks Industry classification. It is currently ranked 3, placing it in top 19%.
The fund is sponsored by Invesco. It has amassed assets over $466.50 M, making it one of the average sized ETFs attempting to match the performance of the Healthcare - Broad segment of the equity market. PSCH seeks to match the performance of the S&P SmallCap 600 Capped Health Care Index before fees and expenses.
This Index is comprised of common stocks of U.S. healthcare companies.These are companies that are principally engaged in the business of providing healthcare-related products & services, including biotechnology, pharmaceuticals, medical technology and supplies & facilities and this Index is a subset of the S&P SmallCap 600 Index.
Cost is an important factor in selecting the right ETF, and cheaper funds can significantly outperform their more expensive counterparts if all other fundamentals are the same.
Annual operating expenses for this ETF are 0.29%, making it one of the least expensive products in the space.
Sector Exposure and Top Holdings
Even though ETFs offer diversified exposure that minimizes single stock risk, investors should also look at the actual holdings inside the fund. Luckily, most ETFs are very transparent products that disclose their holdings on a daily basis.
This ETF has heaviest allocation in the Healthcare sector--about 100% of the portfolio.
Looking at individual holdings, Neogen Corp (NEOG) accounts for about 4.25% of total assets, followed by Repligen Corp (RGEN) and Lhc Group Inc (LHCG).
The top 10 holdings account for about 33.69% of total assets under management.
Performance and Risk
So far this year, PSCH has added roughly 9.83%, and is down about -16.60% in the last one year (as of 09/23/2019). During this past 52-week period, the fund has traded between $100.46 and $140.42.
The ETF has a beta of 1.23 and standard deviation of 19.11% for the trailing three-year period, making it a high risk choice in the space. With about 73 holdings, it effectively diversifies company-specific risk.
Invesco S&P SmallCap Health Care ETF carries a Zacks ETF Rank of 3 (Hold), which is based on expected asset class return, expense ratio, and momentum, among other factors. Thus, PSCH is a reasonable option for those seeking exposure to the Health Care ETFs area of the market. Investors might also want to consider some other ETF options in the space.
Vanguard Health Care ETF (VHT) tracks MSCI US Investable Market Health Care 25/50 Index and the Health Care Select Sector SPDR Fund (XLV) tracks Health Care Select Sector Index. Vanguard Health Care ETF has $9.06 B in assets, Health Care Select Sector SPDR Fund has $17.23 B. VHT has an expense ratio of 0.10% and XLV charges 0.13%.
To learn more about this product and other ETFs, screen for products that match your investment objectives and read articles on latest developments in the ETF investing universe, please visit Zacks ETF Center.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Invesco S&P SmallCap Health Care ETF (PSCH): ETF Research Reports
Health Care Select Sector SPDR Fund (XLV): ETF Research Reports
Vanguard Health Care ETF (VHT): ETF Research Reports
Neogen Corporation (NEOG) : Free Stock Analysis Report
Repligen Corporation (RGEN) : Free Stock Analysis Report
LHC Group, Inc. (LHCG) : Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research